nach oben

Erschienen in:

01.09.2008 | Article

A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes

verfasst von: D. Gong, J. Lu, X. Chen, S. Reddy, D. J. Crossman, S. Glyn-Jones, Y.-S. Choong, J. Kennedy, B. Barry, S. Zhang, Y.-K. Chan, K. Ruggiero, A. R. J. Phillips, G. J. S. Cooper

Erschienen in: Diabetologia | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The selective Cu^II chelator triethylenetetramine (TETA) extracts systemic Cu^II into the urine of diabetic humans and rats as a model of diabetes, and in the process also normalises hallmarks of diabetic heart disease. However, the role of Cu and its response to TETA in animals with diabetic nephropathy were previously unknown. Here, we report the effects of TETA treatment on Cu and other essential elements, as well as on indices of renal injury and known pathogenic molecular processes, in kidneys from a rat model of diabetes.

Methods

Rats at 8 weeks after streptozotocin-induction of diabetes were treated with oral TETA (34 mg/day in drinking water) for a further 8 weeks and then compared with untreated diabetic control animals.

Results

Renal tissue Cu was substantively elevated by diabetes and normalised by TETA, which also suppressed whole-kidney and glomerular hypertrophy without lowering blood glucose. The urinary albumin: creatinine ratio was significantly elevated in the rat model of diabetes but lowered by TETA. Total collagen was also elevated in diabetic kidneys and significantly improved by TETA. Furthermore, renal cortex levels of TGF-β1, MAD homologue (SMAD) 4, phosphorylated SMAD2, fibronectin-1, collagen-III, collagen-IV, plasminogen activator inhibitor-1 and semicarbazide-sensitive amine oxidase all tended to be elevated in diabetes and normalised by TETA.

Conclusions/interpretation

Dysregulation of renal Cu homeostasis may be a key event eliciting development of diabetic nephropathy. Selective Cu^II chelation can protect against pathogenic mechanisms that lead to or cause diabetic nephropathy and might be clinically useful in the treatment of early-stage diabetic kidney disease.

Nur mit Berechtigung zugänglich

Susztak K, Raff AC, Schiffer M, Bottinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–233PubMedCrossRef

Roberts AB, McCune BK, Sporn MB (1992) TGF-beta: regulation of extracellular matrix. Kidney Int 41:557–559PubMedCrossRef

Yamamoto T, Nakamura T, Noble NA (1993) Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814–1818PubMedCrossRef

Bruijn RA, Roos A, de Geus B (1994) Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology. J Lab Clin Med 123:34–47PubMed

Haralson MA (1997) Transforming growth factor-beta, other growth factors, and the extracellular matrix. J Lab Clin Med 130:455–458PubMedCrossRef

Cooper GJS, Phillips ARJ, Choong SY et al (2004) Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53:2501–2508PubMedCrossRef

Cooper GJS, Chan Y-K, Dissanayake AM et al (2005) Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 54:1468–1476PubMedCrossRef

Gong D, Lu J, Chen X et al (2006) Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats. Mol Pharmacol 70:2045–2051PubMedCrossRef

Leblondel G, Allain P (1988) Altered element concentrations in tissues of spontaneously hypertensive rats. Biomed Pharmacother 42:121–129PubMed

10.

Minakata K, Kawai K, Horio F, Takeuchi H, Suzuki O (2004) Accumulation of copper in kidney of spontaneously hypertensive rats, a preliminary study. Biofactors 22:29–31PubMed

11.

Ito S, Fujita H, Narita T et al (2001) Urinary copper excretion in type 2 diabetic patients with nephropathy. Nephron 88:307–312PubMedCrossRef

12.

Boomsma F, van den Meiracker AH, Winkel S, Man in’t Veld AJ, Schalekamp MA (1999) Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first diagnosis. Diabetologia 42:233–237PubMedCrossRef

13.

Mathys KC, Ponnampalam SN, Padival S, Nagaraj RH (2002) Semicarbazide-sensitive amine oxidase in aortic smooth muscle cells mediates synthesis of a methylglyoxal-AGE: implications for vascular complications in diabetes. Biochem Biophys Res Commun 297:863–869PubMedCrossRef

14.

Stolen CM, Madanat R, Marti L et al (2004) Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 18:702–704PubMed

15.

Askari FK, Dick R, Mao M, Brewer GJ (2004) Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Biol Med 229:857–863

16.

Geist J, Werner I, Eder KJ, Leutenegger CM (2007) Comparisons of tissue-specific transcription of stress response genes with whole animal endpoints of adverse effect in striped bass (Morone saxatilis) following treatment with copper and esfenvalerate. Aquatic Toxicol 85:28–39CrossRef

17.

Song M, Deaciuc I, Song Z et al (2008) Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 325:409–416PubMedCrossRef

18.

Liu D, Razzaque MS, Cheng M et al (2001) The renal expression of heat shock protein 47 and collagens in acute and chronic experimental diabetes in rats. Histochem J 33:621–628PubMedCrossRef

19.

Wilson G, Leiter EH (1999) Streptozotocin interactions with pancreatic beta cells and the induction of insulin-dependent diabetes. Curr Top Microbiol Immunol 156:27–54

20.

Bertrand M, Weber G, Schoefs B (2003) Metal determination and quantification in biological materials using particle induced X-ray emission. Trends Anal Chem 22:254–262CrossRef

21.

Reddy GK, Enwemeka CS (1996) A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29:225–229PubMedCrossRef

22.

de Zeeuw D, Remuzzi G, Parving H-H et al (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65:2309–2320PubMedCrossRef

23.

Chen L, Wang Y, Tay YC, Harris DC (1997) Proteinuria and tubulointerstitial injury. Kidney Int 61:S60–S62

24.

Saunders GK (1986) The effects of excess renal copper on kidney function in the diabetic rat. Res Commun Chem Pathol Pharmacol 52:45–49PubMed

25.

Walshe JM (1982) Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1:643–647PubMedCrossRef

26.

Kodama H, Murata Y, Itsuka T, Abe T (1997) Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci 61:899–907PubMedCrossRef

27.

Ziyadeh FN (2004) Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 15:S55–S57PubMedCrossRef

28.

O’Conner-McCourt MD, Wakefield LM (1987) Latent transforming growth factor beta in serum. J Biol Chem 262:14090–14099

29.

Yamaguchi Y, Mann DM, Ruoslahti E (1990) Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346:281–284PubMedCrossRef

30.

Massagué J, Chen YG (2000) Controlling TGF-beta signalling. Genes Dev 14:627–644PubMed

31.

Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH (1994) SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 125:929–943PubMedCrossRef

32.

Strandjord TP, Madtes DK, Weiss DJ, Sage EH (1999) Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol 277:L628–L635PubMed

33.

Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH (2003) Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141:210–216PubMedCrossRef

34.

Lee HB, Ha H (2005) Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology 10:S11–S13PubMedCrossRef

35.

Rerolle JP, Vigneau C, Hertig A, Berrou J, Rondeau E (2001) Plasminogen activator inhibitor type 1: physiology and role in renal physiopathology. Nephrology 22:5–13

36.

Langford SD, Trent MB, Boor PJ (2002) Semicarbazide-sensitive amine oxidase and extracellular matrix deposition by smooth-muscle cells. Cardiovasc Toxicol 2:141–150PubMedCrossRef

37.

Ahmed MU, Thorpe SR, Baynes JW (1996) Identification of N-(carboxymethyl)lysine as a degradation product of fructose lysine in glycated protein. J Biol Chem 261:4889–4894

38.

Williams ME (2006) New potential agents in treating diabetic kidney disease: the fourth act. Drugs 66:2287–2298PubMedCrossRef

39.

Nazratun N, Mahmood AA, Kuppusamy UR, Ahmad TS, Tan SY (2006) Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vascular Med 11:245–250CrossRef

40.

Qian M, Liu M, Eaton JW (1998) Transition metals bind to glycated proteins forming redox active “glycochelates”: implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 250:385–389PubMedCrossRef

41.

Cai L, Chen S, Evans T, Cherian MG, Chakrabarti S (2002) Endothelin-1-mediated alteration of metallothionein and trace metals in the liver and kidneys of chronically diabetic rats. Int J Exp Diabetes Res 3:193–198PubMedCrossRef

42.

Kodama H, Murata Y (1999) Molecular genetics and pathophysiology of Menkes’ disease. Pediatr Int 41:430–435PubMedCrossRef

43.

Ozawa H, Kodama H, Kawaguchi H, Mochizuki T, Kobayashi M, Igarashi T (2003) Renal function in patients with Menkes’ disease. Eur J Pediatr 162:51–52PubMedCrossRef

44.

Leu ML, Strickland GT, Gutman RA (1970) Renal function in Wilson’s disease: response to penicillamine therapy. Am J Med Sci 260:381–398PubMedCrossRef

45.

Hayashi M, Miyane K, Senou M et al (2005) Inhibitory effects of trientine, a copper-chelating agent, on induction of DNA strand breaks in kidney cells of Long-Evans cinnamon (LEC) rats. Exp Anim 54:403–412PubMedCrossRef

46.

Tsujikawa K, Suzuki N, Shimaoka T et al (1994) Abnormal accumulation of copper-metallothionein in the liver and kidney of Long-Evans rats with a cinnamon-like coat color (LEC rats). Biol Pharm Bull 17:591–595PubMed

47.

Sumi Y, Kawahara S, Kikuchi Y, Sawada J, Suzuki T, Suzuki KT (1993) Histochemical and immunohistochemical localization of copper, iron and metallothionein in the liver and kidney of LEC rats. Acta Histochem Cytochem 26:5–9

48.

Suzuki-Kurasaki M, Okabe M, Kurasaki M (1997) Copper-metallothionein in the kidney of macular mice: a model of Menkes’ disease. J Histochem Cytochem 45:1493–1501PubMed

49.

Chen ML, Failla ML (1988) Metallothionein metabolism in the liver and kidney of the streptozotocin-diabetic rat. Comp Biochem Physiol B 90:439–445PubMedCrossRef

50.

Wichmann KA, Boyd PDW, Söhnel T, Allen GR, Phillips ARJ, Cooper GJS (2007) Characterization of dicarboxylic salts of protonated triethylenetetramine useful for the treatment of copper-related pathologies. Cryst Growth Des 7:1844–1850CrossRef

Titel: A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes
verfasst von: D. Gong
J. Lu
X. Chen
S. Reddy
D. J. Crossman
S. Glyn-Jones
Y.-S. Choong
J. Kennedy
B. Barry
S. Zhang
Y.-K. Chan
K. Ruggiero
A. R. J. Phillips
G. J. S. Cooper
Publikationsdatum: 01.09.2008
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2008
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-008-1088-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes